XCUR News and Press, Exicure Inc. From 12/13/21

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Exicure To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - December 13, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm...

– Exicure will reduce its workforce by approximately 50%, along with the implementation of other cost-cutting measures – – Company to wind down immuno-oncology program cavrotolimod (AST-008) and XCUR-FXN preclinical program for the treatment of Friedreich’...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Exicure To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - November 26, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm,...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Exicure To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - November 24, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm,...

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Exicure, Inc. (“Exicure” or the “Company”) (NASDAQ: XCUR) on behalf of Exicure stockholders. Our investigation concerns whether Exi...

Exicure (NASDAQ:XCUR): Q3 GAAP EPS of -$0.27 misses by $0.17. Revenue of -$3.68M (-250.8% Y/Y) may not be comparable with the consensus of $6.99M Press Release Cash, cash equivalents, short-term investments, and restricted cash were $62.0M as of September 30, 2021 compared to $57.3M as of Jun...

Exicure, Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported financial results for the quarter ended September 30, 2021 and provided an update on corporate progress. ȁ...

Gainers: BIMI International Medical (NASDAQ:BIMI) +55%. Kezar Life Sciences (NASDAQ:KZR) +31%. CNS Pharmaceuticals (NASDAQ:CNSP) +28%. ReTo Eco-Solutions (NASDAQ:RETO) +28%. Progenity (NASDAQ:PROG) +27%. PLBY Group (NASDAQ:PLBY) +27%. IonQ (NYSE:IONQ) +25%. Kuke (NYSE:KUKE) +21%. On Holding (...

Exicure (XCUR -25.6%) has filed a Form 12b-25 with U.S. SEC related to its quarterly report on Form 10-Q for the period ended Sep.30. The company is unable to file its report within the prescribed time period without unreasonable effort or expense. On Nov. 9, 2021, the Audit Committ...

Gainers: Kezar Life Sciences KZR +36%, Progenity (NASDAQ:PROG) +28%, GeoVax Labs GOVX +15%, Medicenna Therapeutics (NASDAQ:MDNA) +15%, Amarin AMRN +10%. Losers: Talkspace TALK -37%, OptiNose OPTN -34%, Molecular Partners MOLN&#x...